Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer
Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer
Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer
Statut
Status :
Terminé
Type d'étude
Phase II
Age Min.
18
Ans
Age Max.
-
Genre
Femme
Aire thérapeutique :
Oncologie
Maladie :
Cancer du sein
Traitement :
Vinorelbine (Navelbine® Oral)
Phase :
Phase II
Date de début de l'étude :
Mars 2004
End date :
21 Mai 2019
Identifiant de l'essai :
PM0259 CA 215 B0
Identifiant EudraCT/CTIS :
2004-000748-26
Envoyer par email